Trial Profile

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2021 According to a Spectrum Pharmaceuticals media release, a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS (eflapegrastim) from this trial will be presented as part of the 38th Annual Miami Breast Cancer Conference taking place virtually 4th to 7th Mar 2021.
12 Aug 2020 Results, analysis of data from 3 trails (one phase II and 2 phase III studies) assessing the fixed dose of Eflapegrastim in patients receiving Docetaxel-Cyclophosphamide chemotherapy, published in the Journal of Clinical Pharmacology
27 Dec 2018 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com